Literature DB >> 17762637

The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren.

Joël Ménard, Michel Azizi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762637     DOI: 10.1097/HJH.0b013e3282ef45e9

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


× No keyword cloud information.
  11 in total

Review 1.  Direct renin inhibition: an analysis of possible benefits.

Authors:  Brian K Dockery; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

Review 2.  Now that we have a direct renin inhibitor, what should we do with it?

Authors:  Alice Stanton
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study.

Authors:  Satoru Kuriyama; Keitaro Yokoyama; Yoichiro Hara; Naoki Sugano; Takashi Yokoo; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2013-11-20       Impact factor: 2.801

Review 4.  Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Authors:  Christian Werner; Janine Pöss; Michael Böhm
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 5.  RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Authors:  Christian Werner; Magnus Baumhäkel; Koon K Teo; Roland Schmieder; Johannes Mann; Thomas Unger; Salim Yusuf; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2008-05-03       Impact factor: 5.460

Review 6.  Are we poised to target ACE2 for the next generation of antihypertensives?

Authors:  Anderson J Ferreira; Mohan K Raizada
Journal:  J Mol Med (Berl)       Date:  2008-05-01       Impact factor: 4.599

Review 7.  Direct renin inhibition: clinical pharmacology.

Authors:  Michel Azizi
Journal:  J Mol Med (Berl)       Date:  2008-03-27       Impact factor: 4.599

8.  Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.

Authors:  Raymond R Townsend; Alan D Forker; Vaishali Bhosekar; Anthony Yadao; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-11       Impact factor: 3.738

9.  Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

Review 10.  Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Vasc Health Risk Manag       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.